Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru.
Drug resistance
Levofloxacin
Moxifloxacin
Ofloxacin
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
14 Nov 2021
14 Nov 2021
Historique:
received:
09
08
2021
accepted:
03
11
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
17
11
2021
Statut:
epublish
Résumé
To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. There were 279 M. tuberculosis isolates from the two cohorts (2004-2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0-0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0-0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.
Identifiants
pubmed: 34776013
doi: 10.1186/s13104-021-05832-0
pii: 10.1186/s13104-021-05832-0
pmc: PMC8591909
doi:
Substances chimiques
Antitubercular Agents
0
Fluoroquinolones
0
Pharmaceutical Preparations
0
Levofloxacin
6GNT3Y5LMF
Moxifloxacin
U188XYD42P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
413Subventions
Organisme : NIH HHS
ID : AI065298
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Int J Infect Dis. 2011 Mar;15(3):e211-6
pubmed: 21195001
Antimicrob Agents Chemother. 2011 Dec;55(12):5421-9
pubmed: 21876059
J Antimicrob Chemother. 2009 Jun;63(6):1173-8
pubmed: 19329799
Int J Antimicrob Agents. 2013 Sep;42(3):232-7
pubmed: 23806638
Am J Respir Crit Care Med. 2009 Aug 15;180(4):365-70
pubmed: 19483111
Rev Peru Med Exp Salud Publica. 2017 Apr-Jun;34(2):299-310
pubmed: 29177392
Eur Respir J. 2013 Jul;42(1):156-68
pubmed: 23100499
Int J Tuberc Lung Dis. 2012 Sep;16(9):1162-7
pubmed: 22794509
Int J Tuberc Lung Dis. 2016 Dec 1;20(12):42-47
pubmed: 28240572
N Engl J Med. 2021 May 6;384(18):1705-1718
pubmed: 33951360
Curr Top Med Chem. 2003;3(3):249-82
pubmed: 12570763
Eur Respir J. 2019 Oct 10;54(4):
pubmed: 31601719
Eur Respir J. 2012 Oct;40(4):814-22
pubmed: 22653774
Arch Intern Med. 2007 Nov 26;167(21):2317-22
pubmed: 18039990
Clin Infect Dis. 2016 Oct 1;63(7):e147-e195
pubmed: 27516382
Am J Med. 2005 Mar;118(3):259-68
pubmed: 15745724
Korean J Intern Med. 2019 Mar;34(2):344-352
pubmed: 30045614
BMC Infect Dis. 2012 Aug 16;12:193
pubmed: 22898609